DC-targeting as a route to enhance the potency of cancer vaccines has been explored previously, with targeting of antigen to DC-specific markers such as XCR1 [33,34], Clec9A [51,52] and DEC205 [53,54]. This evidence concerns the gene XCR1 and cancer.